MOSCOW (Reuters): Indian pharmaceutical company Hetero will manufacture over 100 million doses of the Russian Sputnik V Covid-19 vaccine per year under the terms of a deal unveiled on Friday (Nov 27) between it and Russia’s RDIF sovereign wealth fund.
The move, which RDIF cast as another step in its efforts to scale up international manufacturing of its flagship vaccine, will see Hetero begin production in India at the start of next year, according to a joint statement on the Sputnik V Twitter account.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
